10/18/2024

Janusmed sex and gender

Janusmed sex and gender – cilgavimab

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Cilgavimab

Cilgavimab

Class : A

Show all info

Print

Contact us

  1. Evusheld (tixagevimab, cilgavimab). AstraZeneca AB. EMA EPAR Scientific Discussion. Published 28/04/2022.

  2. Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022;386(23):2188-2200.

  3. Montgomery H, Hobbs FDR, Padilla F, Arbetter D, Templeton A, Seegobin S et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022.

  4. ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. Lancet Respir Med. 2022.

  5. EudraVigilance. Amsterdam: European Medicines Agency (EMA). 2022 [updated 2022-08-13, cited 2022-08-17.]

  1. Evusheld (tixagevimab, cilgavimab). AstraZeneca AB. EMA EPAR Scientific Discussion. Published 28/04/2022.
  2. Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022;386(23):2188-2200.
  3. Montgomery H, Hobbs FDR, Padilla F, Arbetter D, Templeton A, Seegobin S et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022.
  4. ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. Lancet Respir Med. 2022.
  5. EudraVigilance. Amsterdam: European Medicines Agency (EMA). 2022 [updated 2022-08-13, cited 2022-08-17.]